Cormorant Asset Management »

Rapport Therapeutics shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $95M 3.2M 29.70
2025-06-30 $33M 2.9M 11.37
2025-03-31 $30M 2.9M 10.03
2024-12-31 $52M 2.9M 17.74
2024-09-30 $60M 2.9M 20.48
2024-06-30 $68M 2.9M 23.26

More positions owned by Cormorant Asset Management

Bridgebio Oncology Therapeut Com New
Abivax Sa Sponsored Ads (ABVX)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Bridgebio Pharma (BBIO)
Edgewise Therapeutics (EWTX)
Bright Minds Biosciences Com New (DRUG)
Arcellx Common Stock (ACLX)
Insmed Com Par $.01 (INSM)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Praxis Precision Medicines I Com New (PRAX)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Pharvaris N V (PHVS)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Gh Research Ordinary Shares (GHRS)

View all positions for Cormorant Asset Management

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Capital Research and Management Company - Division 3
Cormorant Asset Management
Goldman Sachs Group
Sofinnova Ventures
Johnson & Johnson
Vanguard Group
BlackRock
Baker Bros. Advisors
Siren
Trv Gp Vi
Vestal Point Capital
Polar Capital Holdings

View all funds holding Rapport Therapeutics